Skip to Main Content

Major drug makers are getting into mRNA, the technology behind the Moderna and Pfizer-BioNTech Covid vaccines, in a big way.

Sanofi, one of the largest vaccine makers, announced Tuesday it will spend $3.2 billion to purchase Translate Bio, its partner in an effort to create an mRNA-based Covid-19 vaccine. That follows a June announcement that Sanofi would create an mRNA vaccines center of excellence, funded with almost $500 million annually, with the goal of creating six experimental vaccine candidates by 2025.


“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” said Paul Hudson, Sanofi’s CEO, in a statement. Translate Bio’s CEO, Ronald Renaud, said the deal means his company’s technology “is now even better positioned to reach more people, faster.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.